AzTrials
AzTrials

Tourette SyndromeLISA-TSNCT04851678

Longitudinal Impact of Stressors in Adults With Tourette Syndrome

An observational study of Tourette Syndrome, run by Vanderbilt University Medical Center at 1 site in United States.

Recruiting

Looking for participants now. Contact the study team or a site below to ask about taking part.

Sites and contacts
Official record
Search all trials

Trial summary

The Investigators propose a two-year, longitudinal pilot study of TS adults (>18) to determine impact of lifetime environmental stress exposure on tic severity, psychiatric comorbidity severity, and health-related quality of life (HRQOL). Read more about this study

Who is it for?
Ages 18 years and older
Conditions the study is for
Tourette Syndrome
What is being tested?
None - observational study
How many people
140 participants
Where
1 siteUnited States
Study dates
30 Sep 2021to 30 Jun 2027
Phase
Observational
Are there results?
Not yet: the study is under way

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 years and older
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: adults (>18 years of age) with Tourette syndrome or other chronic tic disorder

Who may be able to join

  • adults (>18) meeting Diagnostic and Statistics Manual, 5th edition (DSM-V) criteria for Tourette syndrome, chronic motor tic disorder, or chronic vocal tic disorder
  • ability to provide informed consent
  • English proficiency

Who cannot join

  • significant medical, neurologic, or psychiatric diagnoses (e.g. uncontrolled epilepsy, chronic heart failure, schizophrenia) besides TS and its commonly co-occurring psychiatric diagnoses

Trial locations and contacts

1 site in 1 country. Contact the study team or a site near you to ask about taking part.

Michelle Eckland, BS contact

615-875-7394

michelle.r.eckland.1@vumc.org

United States1 site, 1 recruiting
  • Vanderbilt University Medical Center

    Nashville, Tennessee, 37232-5400

    Michelle Eckland, BS, 6159362025, michelle.r.eckland.1@vumc.org

    David Isaacs, MD, MPH

    Recruiting

Other trials in United States

About this study

The Investigators propose a two-year, longitudinal pilot study of TS adults (>18) to determine impact of lifetime environmental stress exposure on tic severity, psychiatric comorbidity severity, and health-related quality of life (HRQOL).

Read the detailed description

Tourette syndrome (TS) is a widely prevalent neurodevelopmental disorder with limited treatment options,(1,2) substantial impact on quality of life in children(3-7) and adults,(4,8-10) and two-fold increased risk of premature death.(11,12) Tics are the defining feature of TS, and as a result, TS is often narrowly perceived in terms of tics alone. Tics themselves tend to wane in late adolescence, with distressing tics persisting in only one-third of TS patients.(13) Because tics generally diminish with age, the plight of adults with TS is often neglected. Over half of TS adults suffer from anxiety and depression,(10,14) and a similar percentage experience symptoms of attention deficit hyperactivity disorder (ADHD) and obsessive-compulsive disorder (OCD), findings recently corroborated in our own clinical population.(10) Many TS adults struggle to form meaningful relationships with peers, and one-third feel inadequately supported by their families.(13) The burden of TS in adulthood extends beyond mental and social health. In a national registry cohort study, individuals with TS had a mortality rate ratio of 1.8 relative to healthy controls, even after controlling for comorbid psychiatric diagnoses.(11) The causes of more frequent premature death in TS populations are unclear, with many mechanisms implicated, including suicide,(15) traumatic accidents,(12) substance abuse,(16) metabolic disorders,(12,17) and complications from pharmacotherapy.(18,19)

Environmental stressors are also postulated to impact the course of TS.(20) An environmental stressor is any external condition or event that poses a threat to an individual's well-being.(21) Such stressors are known to alter brain development(22-24) and increase risk of adulthood psychopathology.(25,26) A single study has explored the role of environmental stressors in TS, finding that selected stressors predicted two-year tic and psychiatric symptom severity in a pediatric cohort (n=37 patients).(27) No similar investigations have been undertaken in TS adults. The Investigators hypothesize that environmental stressors are risk factors for more severe adult TS phenotype. The Investigators propose a two-year, longitudinal pilot study of TS adults (>18) to determine impact of lifetime environmental stress exposure on tic severity, psychiatric comorbidity severity, and health-related quality of life (HRQOL).

Aim 1. Determine influence of lifetime environmental stressors on tic severity in TS adults. Hypothesis: Number of lifetime stressors at baseline assessment is associated with greater tic severity at two year follow-up. Seventy adults with TS will be recruited from the Vanderbilt TS Clinic to complete a baseline assessment, consisting of validated clinical rating scales for tic severity (Yale Global Tic Severity Scale), common psychiatric comorbidities, and lifetime environmental stressors (Stress and Adversity Inventory for Adults, STRAIN). Because acute and chronic stressors exert differential physiologic and clinical-level effects,(28-31) the STRAIN assesses these separately. The Investigators will use multivariable linear regression to examine the influence of acute and chronic lifetime stressor count at baseline on tic severity at two years, controlling for baseline tic severity and psychiatric comorbidities, as well as anti-tic medications at follow-up. Results will clarify the impact of environmental stressors on tic severity in TS adults.

Aim 2. Determine influence of lifetime environmental stressors on depression in TS adults.

Hypothesis: Number of lifetime stressors at baseline assessment is associated with more depressive symptoms at two-year follow-up. Depression is the psychiatric symptom that most impacts adult functioning and QOL.(10) As part of baseline and follow-up assessments, Aim 1 participants will complete standardized, semi-structured psychiatric interviews (Mini International Neuropsychiatric Interview, MINI) and validated self-report depression scales (NeuroQOL-Depression). The statistical approach from Aim 1 will be adopted to examine the influence of acute and chronic lifetime stressor count at baseline on depression symptom severity at two years, again controlling for select confounds. Findings will delineate the effects of acute and chronic environmental stressors on depression in adults with TS.

Aim 3. Determine influence of positive childhood experiences on health-related quality of life (HRQOL) in TS adults. Hypothesis: Greater number of positive childhood experiences is associated with better HRQOL in TS adults at two-year follow-up. Positive childhood experiences partially mitigate the negative effects of adverse childhood experiences.(32) At baseline and follow-up visits, Aim 1 participants will report number and type of positive childhood experiences. They will also complete a validated HRQOL measure specific to TS: the Gilles de la Tourette-Quality of Life Scale (GTS-QOL). The Investigators will use multivariable regression modeling to examine the influence of positive childhood experiences on future HRQOL, controlling for environmental stressors and baseline HRQOL. Results will elucidate the potentially moderating role of positive childhood experiences on HRQOL in TS adults.

Being tested
None - observational study
Keywords
Stress, Environmental stress, Psychosocial stress
Medical subject headings
Tourette Syndrome

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • None - observational studyOther

    None - observational study

Study groups in NCT04851678
Study groupRoleWhat they receive
Individuals with Tourette syndrome (TS)Individuals previously diagnosed with Tourette syndrome (TS). Participants must be 18 years of age or older.
Receives: Other: None - observational study

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Total Tic Score from Yale Global Tic Severity Scale (YGTSS)

    Semi-structured, clinician-administered interview to assess tic severity. Total tic scores are a composite of motor tic scores (0-25) and phonic tic scores (0-25) based on 5 dimensions of tic severity: number, frequency, intensity, complexity, and interference. Total tic scores range from 0-50. Higher scores indicate great tic severity. The YGTSS is the gold-standard clinical rating scale for tic severity.

    Measured: 2 years post-baseline assessment

  2. NeuroQOL-Depression Score

    NeuroQOL-Depression is a validated, 8-item self-report scale assessing symptoms of depression. Raw total scores range from 8-40; raw scores are converted to T-scores based on normative samples. Higher scores indicate more depressive symptoms. NeuroQOL-Depression is part of the Neuro-QOL (Quality of Life in Neurological Disorders) measurement system. The scale is designed to be completed with one minute.

    Measured: 2 years post-baseline assessment

  3. Gilles de la Tourette Quality of Life Scale (GTS-QOL) Score

    The GTS-QOL is a 27-item self-report scale. Respondents rate each item on a Likert scale ranging from 0 ("no problem") to 4 ("extreme problem"). The scale is composed of four sub-scales: Psychological (11 items), Physical/Activities of Daily Living (Physical/ADL) (7 items), Obsessive-Compulsive (OC) (5 items), and Cognitive (4 items) (39). Item scores within each subscale are summed and then normalized to 100 to generate the subscale score. The four subscale scores are then summed and normalized to 100 to yield the total score. Higher scores indicate worse health-related quality of life.

    Measured: 2 years post-baseline assessment

Secondary outcomes (10)
  1. NeuroQOL-Anxiety Score

    NeuroQOL-Depression is a validated, 8-item self-report scale assessing symptoms of anxiety. Raw total scores range from 8-40; raw scores are converted to T-scores based on normative samples. Higher scores indicate more anxiety symptoms. NeuroQOL-Anxiety is part of the Neuro-QOL (Quality of Life in Neurological Disorders) measurement system. The scale is designed to be completed with one minute.

    Measured: 2 years post-baseline assessment

  2. Adult ADHD Self-Report Screening Scale for DSM-V (ASRS-V) Score

    ASRS-V is a 6-question scale screening for symptoms of inattention and hyperactivity. Each item is rated 0 ("never") to 4 ("very often"). Total score is the sum of individual item scores. Higher score indicates more ADHD symptoms. In clinical populations, ASRS-V total score cutoff ≥ 14 is 81% sensitive and 70% specific for detecting ADHD.

    Measured: 2 years post-baseline assessment

  3. Dimensional Obsessive-Compulsive Scale (DOCS) Score

    DOCS is a 20-item, validated self-report scale assessing for severity of obsessive-compulsive symptoms. Total score ranges from 0-80, with higher scores indicating more OCD symptoms. In clinical populations, DOCS total score cutoff ≥ 21 is 70% sensitive and 70% specific in distinguishing OCD from other anxiety disorders.

    Measured: 2 years post-baseline assessment

  4. Mini International Neuropsychiatric Interview (MINI)

    The Mini-International Neuropsychiatric Interview (M.I.N.I.) is a brief structured diagnostic interview for common DSM-V psychiatric disorders. Scale administration is typically 15-20 minutes. Scale output is presence/absence of psychiatric diagnoses currently and/or in the past.

    Measured: 2 years post-baseline assessment

  5. Lifetime Adult STRAIN

    The STRAIN (https://www.uclastresslab.org/projects/strain-stress-and-adversity-inventory/) is a NIMH/RDoC-recommended online stress assessment system that measures individuals' lifetime exposure to different types of acute and chronic stress that have implications for health. STRAIN questions automatically adapt based on a user's responses. The STRAIN generates multiple stressor scores, including total stressor count and severity, childhood and adulthood stressor counts and severities, and domain-specific stressor counts and severities.

    Measured: 2 years post-baseline assessment

  6. Multifactoral Assessment of Perceived Social Support (MAPSS)

    The MAPSS is an 8-item, unidimensional, validated, clinically relevant, self-report measure of social support.

    Measured: 2 years post-baseline assessment

  7. Sensory Gating Inventory (SGI)

    The SGI is a 36-item, validated instrument assessing hyper- or hypo-sensitivity to sensory stimuli (primarily sight and sound). Each scale item is a statement to which participants must rate their agreement on a 6-point Likert scale (1 = "never true"; 6 = "always true"). The minimum score on the scale is 36; the maximum score is 216. Higher scores indicate more abnormal sensory experiences.

    Measured: 2 years post-baseline assessment

  8. Body Perception Questionnaire-Short Form (BPQ-SF)

    The BPQ-SF is a self-report questionnaire that assesses the frequency of specific body stress reactions in organs that are innervated by the autonomic nervous system. Combined scores from organs throughout the body provide a measure of autonomic stress response patterns. The questionnaire has been used in a range of international neural, behavioral, and clinical studies and translated into several languages.

    Measured: 2 years post-baseline assessment

  9. Emotion Regulation Questionnaire

    The Emotion Regulation Questionnaire is a 10-item, self-report questionnaire designed to assess individual differences in the habitual use of two emotion regulation strategies: cognitive reappraisal and expressive suppression. Participants rate each statement about emotion regulation on a 7-point Likert scale (1 = "strongly disagree"; 7 = "strongly agree").

    Measured: 2 years post-baseline assessment

  10. Response to Stress Questionnaire-Interpersonal Stress (RSQ)

    The RSQ measures coping and involuntary stress responses. It begins with a checklist of stressors that pertain to interpersonal stress, which the participant rates in terms of how often each stressor has occurred in the recent past. The questionnaire then asks the participant to keep those specific stressors in mind when responding to the items that comprise the stress responses. Participants rate how often they use each coping method or experience each type of involuntary stress response on a scale of 1 (Not at all) to 4 (A lot). Some items require participants to select an answer on the 1 to 4 scale and write in additional information to describe specifically how they employed that particular coping strategy. The RSQ contains items to measure three types of coping and two types of involuntary stress responses. The measure thus yields five factors: primary control coping, secondary control coping, disengagement coping, involuntary engagement, and involuntary disengagement.

    Measured: 2 years post-baseline assessment

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted20 Apr 2021
  2. Study start30 Sep 2021
  3. Primary completion1 Mar 2027 (estimated)
  4. Study completion30 Jun 2027 (estimated)

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Prospective
Enrolment
140 participants (estimated)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04851678
Sponsor's protocol ID
U12134
Acronym
LISA-TS
Status last verified
Apr 2026
First submitted
14 Apr 2021
Last updated
5 May 2026
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
Undecided

Questions about this trial

What is this clinical trial studying?

An observational study of Tourette Syndrome, run by Vanderbilt University Medical Center at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: looking for participants now, as of the sponsor's last update on 5 May 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

This study is still under way. Results are not available in the source record yet.

How can a doctor refer a patient or contact the research team?

Contact Michelle Eckland, BS (615-875-7394, michelle.r.eckland.1@vumc.org), or a site near the patient. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Total Tic Score from Yale Global Tic Severity Scale (YGTSS) (time frame: 2 years post-baseline assessment). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 5 May 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in